At the moment, the issue of re-treatment of MM patients with an anti-CD38 mAb recognizing a different epitope in order to bypass resistance to the first lacks evidence, also considering the anti-CD38 antibodies that are now included in the therapeutic armamentarium. This evidence concerns the gene CD38 and Miyoshi myopathy.